Application of 31P MR Spectroscopy to the Brain Tumor

다국어 초록 (Multilingual Abstract)

Objective: To evaluate the clinical feasibility and obtain useful parameters of 31P magnetic resonance spectroscopy (MRS) study for making the differential diagnosis of brain tumors.
Materials and Methods: Twenty-eight patients with brain tumorous lesions (22 cases of brain tumor and 6 cases of abscess) and 11 normal volunteers were included. The patients were classified into the astrocytoma group, lymphoma group, metastasis group and the abscess group. We obtained the intracellular pH and the metabolite ratios of phosphomonoesters/phosophodiesters (PME/PDE), PME/inorganic phosphate (Pi), PDE/Pi, PME/adenosine triphosphate (ATP), PDE/ATP, PME/phosphocreatine (PCr), PDE/PCr, PCr/ATP, PCr/Pi, and ATP/Pi, and evaluated the statistical significances.
Results: The brain tumors had a tendency of alkalization (pH = 7.28 ± 0.27, p = 0.090), especially the pH of the lymphoma was significantly increased (pH = 7.45 ± 0.32, p = 0.013). The brain tumor group showed increased PME/PDE ratio compared with that in the normal control group (p = 0.012). The ratios of PME/PDE, PDE/Pi, PME/PCr and PDE/PCr showed statistically significant differences between each brain lesion groups (p < 0.05). The astrocytoma showed an increased PME/PDE and PME/PCr ratio. The ratios of PDE/Pi, PME/PCr, and PDE/PCr in lymphoma group were lower than those in the control group and astrocytoma group. The metastasis group showed an increased PME/PDE ratio, compared with that in the normal control group.
Conclusion: We have obtained the clinically applicable 31P MRS, and the pH, PME/PDE, PDE/Pi, PME/PCr, and PDE/PCr ratios are helpful for differentiating among the different types of brain tumors.

참고문헌 (Reference)

1 Podo F, "Tumour phospholipid metabolism" 12 : 413-439, 1999

2 Oberhaensli RD, "The study of human organs by phosphorus-31 topical magnetic resonance spectroscopy" 60 : 367-373, 1987

3 Keevil SF, "The performance of volume selection sequences for in vivo NMR spectroscopy: implications for quantitative MRS" 19 : 1217-1226, 2001

4 Hirakawa K, "The investigation of experimental brain tumours using 31P-MRS and 1H-MRI" 43 : 140-144, 1988

5 Negendank W, "Studies of human tumors by MRS: a review" 5 : 303-324, 1992

6 Skoch A, "Spectroscopic imaging: basic principles" 67 : 230-239, 2008

7 Okada Y, "Regional metabolism in experimental brain tumors in cats: relationship with acid/ base, water, and electrolyte homeostasis" 77 : 917-926, 1992

8 Albers MJ, "Proton-decoupled 31P MRS in untreated pediatric brain tumors" 53 : 22-29, 2005

9 Heiss WD, "Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors" 31 : 302-310, 1990

10 Maintz D, "Phosphorus-31 MR spectroscopy of normal adult human brain and brain tumours" 15 : 18-27, 2002

11 Cohen JS, "Phospholipid and energy metabolism of cancer cells monitored by 31P magnetic resonance spectroscopy: possible clinical significance" 63 : 1199-1207, 1988

12 Hubesch B, "P-31 MR spectroscopy of normal human brain and brain tumo" 174 : 401-409, 1990

13 Schulz UG, "Normal cortical energy metabolism in migrainous stroke: A 31P-MR spectroscopy study" 40 : 3740-3744, 2009

14 Stubbs M, "Monitoring tumor growth and regression by 31P magnetic resonance spectroscopy" 30 : 217-230, 1990

15 Neeman M, "Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy" 49 : 589-594, 1989

16 Gillies RJ, "MRI of the tumor microenvironment" 16 : 430-450, 2002

17 Aisen AM, "MR spectroscopy: clinical perspective" 173 : 593-599, 1989

18 Estève F, "MR spectroscopy of bilateral thalamic gliomas" 20 : 876-881, 1999

19 Podo F, "MR evaluation of response to targeted treatment in cancer cells" 24 : 648-672, 2011

20 Abraha A, "Inhibition of tumor cell proliferation by dexamethasone: 31P NMR studies of RIF-1 fibrosarcoma cells perfused in vitro" 9 : 173-178, 1996

21 Arias-Mendoza F, "In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multiinstitutional trial" 19 : 504-512, 2006

22 Ng TC, "Human neoplasm pH and response to radiation therapy: P-31 MR spectroscopy studies in situ" 170 (170): 875-878, 1989

23 Park JM, "Human in-vivo 31P MR spectroscopy of benign and malignant breast tumors" 2 : 80-86, 2001

24 Arnold DL, "Characterization of astrocytomas, meningiomas, and pituitary adenomas by phosphorus magnetic resonance spectroscopy" 74 : 447-453, 1991

25 Burkhard T, "Cardiac (31)P-MRS compared to echocardiographic findings in patients with hypertensive heart disease without overt systolic dysfunction--preliminary results" 71 : 69-74, 2009

26 Griffiths JR, "Are cancer cells acidic?" 64 : 425-427, 1991

27 Kemp GJ, "Absolute quantification of phosphorus metabolite concentrations in human muscle in vivo by 31P MRS: a quantitative review" 20 : 555-565, 2007

28 Madden A, "A quantitative analysis of the accuracy of in vivo pH measurements with 31P NMR spectroscopy: assessment of pH measurement methodology" 4 : 1-11, 1991

29 Lehnhardt FG, "1Hand (31)P-MR spectroscopy of primary and recurrent human brain tumors in vitro: malignancy-characteristic profiles of water soluble and lipophilic spectral components" 14 : 307-317, 2001